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Identification of Neuronal Enhancers of the Proopiomelanocortin Gene
by Transgenic Mouse Analysis and Phylogenetic Footprinting
Fla´vio S. J. de Souza,1† Andrea M. Santangelo,1† Viviana Bumaschny,1 Marı´a Elena Avale,1
James L. Smart,2 Malcolm J. Low,2,3,4 and Marcelo Rubinstein1,4,5*
Instituto de Investigaciones en Ingenierı´a Gene´tica y Biologı´a Molecular, CONICET and Departamento Fisiologı´a,
Biologı´a Molecular y Celular, FCEyN, Universidad de Buenos Aires, Buenos Aires, Argentina1; Vollum Institute,2
Department of Behavioral Neuroscience,3 and Center for the Study of Weight Regulation and Associated
Disorders,4 Oregon Health & Science University, Portland, Oregon; and
Centrode Estudios Cientı´ficos, Valdivia, Chile5
The proopiomelanocortin (POMC) gene is expressed in the pituitary and arcuate neurons of the hypothal-
amus. POMC arcuate neurons play a central role in the control of energy homeostasis, and rare loss-of-
function mutations in POMC cause obesity. Moreover, POMC is the prime candidate gene within a highly
significant quantitative trait locus on chromosome 2 associated with obesity traits in several human popula-
tions. Here, we identify two phylogenetically conserved neuronal POMC enhancers designated nPE1 (600 bp)
and nPE2 (150 bp) located approximately 10 to 12 kb upstream of mammalian POMC transcriptional units.
We show that mouse or human genomic regions containing these enhancers are able to direct reporter gene
expression to POMC hypothalamic neurons, but not the pituitary of transgenic mice. Conversely, deletion of
nPE1 and nPE2 in the context of the entire transcriptional unit of POMC abolishes transgene expression in the
hypothalamus without affecting pituitary expression. Our results indicate that the nPEs are necessary and
sufficient for hypothalamic POMC expression and that POMC expression in the brain and pituitary is
controlled by independent sets of enhancers. Our study advances the understanding of the molecular nature
of hypothalamic POMC neurons and will be useful to determine whether polymorphisms in POMC regulatory
regions play a role in the predisposition to obesity.
The proopiomelanocortin (POMC) gene encodes a prohor-
mone expressed at significant levels in three discrete groups of
cells of ectodermal neural plate origin that develop into either
pituitary endocrine cells or brain neurons (54). Cell-specific
posttranslational processing of the POMC prohormone gener-
ates a variety of biologically active peptides that mediate the
mammalian stress response (46). In the pituitary gland, ante-
rior lobe corticotrophs release adenocorticotropic hormone
(ACTH) whereas intermediate lobe melanotrophs further pro-
cess POMC to produce N-acetylated forms of -melanocyte
stimulating hormone (-MSH) and -endorphin. In the brain,
a specialized population of neurons concentrated in the hypo-
thalamic arcuate nucleus also express Pomc, giving rise to -,
-, and -melanocortins and the potent analgesic opioid pep-
tide -endorphin (46, 50).
During the last few years, POMC hypothalamic neurons
have received a great deal of attention because they express
receptors for the adipostatic hormone leptin and play a central
role in the control of energy homeostasis and body weight
regulation (10, 52, 56). Once leptin crosses the blood-brain
barrier, it stimulates both the transcription of the POMC gene
and the activity of POMC arcuate neurons, leading to the
release of melanocortins which, in turn, stimulate central mela-
nocortin receptors to decrease food intake and increase met-
abolic rate (4, 52). The importance of the central melanocortin
pathway in feeding behavior is clearly observed in mice and
humans with null Pomc homozygous mutations, which display
hyperphagia and early-onset obesity (8, 29, 30, 65). Even
though total POMC deficiency is very rare in humans, POMC
is a strong candidate gene to predispose to familial obesity.
Several independent genome-wide scans for quantitative trait
loci (QTL) have found a highly significant genetic linkage
between a relatively narrow region in chromosome 2 contain-
ing the POMC locus and obesity-related traits (11, 15, 47).
However, polymorphisms in the coding sequences of POMC
that alter the structure or function of POMC peptides appar-
ently do not account for this correlation (25), suggesting the
alternative possibility that mutations in noncoding regulatory
sequences may alter the level of POMC RNA transcripts and
consequently the concentration of POMC peptides in the
brain.
Transcriptional regulation of Pomc has been studied primar-
ily in pituitary corticotrophs and melanotrophs because it has
been possible to combine in vitro transfection in immortalized
pituitary cell lines (40) with in vivo expression in transgenic
mice (33, 34). Cell-specific expression of the rat or mouse
Pomc genes in the pituitary is controlled by the combinatorial
presence of cis-acting elements localized within approximately
400 nucleotides adjacent to the transcriptional start site (33,
34). Several transcription factors including Nurr77, NeuroD1/
BETA2 heterodimers, Pitx1, SP1, and Tpit have been impli-
cated in the pituitary regulation of Pomc expression or the
determination of corticotroph and melanotroph lineages (31,
34, 43, 44, 45, 60). In contrast, little is known about enhancer
regions and transcription factors that regulate Pomc expression
* Corresponding author. Mailing address: INGEBI-CONICET,
Vuelta de Obligado 2490, 1428 Buenos Aires, Argentina. Phone: 5411-
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in arcuate neurons. In previous studies, we demonstrated that
the 400-bp proximal Pomc promoter region is incapable of
directing reporter gene expression to the POMC arcuate neu-
rons of transgenic mice (49). However, the inclusion of addi-
tional genomic sequences suggested that cis-acting regions
controlling Pomc expression in the brain are localized within
11 kb of distal 5 flanking sequences upstream of the Pomc
promoter (13, 41, 66). Combining a functional expression anal-
ysis in transgenic mice together with in silico phylogenetic
footprinting, we report here the identification of two conserved
enhancers that are necessary and sufficient for transgene ex-
pression in POMC arcuate neurons. Our results also indicate
that the Pomc promoter has a modular architecture that can
allow independent transcriptional control of Pomc expression
in the brain and the pituitary by a distal and proximal set of
enhancers, respectively. These results advance the understand-
ing of the molecular identity of POMC neurons and might
contribute to a further determination of the role that POMC
plays in feeding centers of the brain and the genetics of obesity.
MATERIALS AND METHODS
Transgenes. Transgenes were constructed using standard molecular cloning
techniques and the pBluescript SK (/) vector (Stratagene). To construct
parental transgene 1, the coding region of enhanced green fluorescent protein
(pEGFP-1, Clontech) followed by the polyadenylation sites from simian virus 40
were inserted into a StuI site located before the translational start codon in exon
2 of a mouse Pomc gene fragment, and subsequent subcloning extended the
flanking regions to 13 and 8 kb from the Pomc gene (13). Based on this
parental construct, transgenes 2, 3, 4, and 6 were constructed by performing
deletions with restriction enzymes SmaI, BamHI-SmaI, NotI-BamHI, and NotI-
EcoRI, respectively. Transgenes 7, 8, and 9 carry deletions of neuronal POMC
enhancer 1 (nPE1) and nPE2, which were introduced using enzymes ApaI-
HindIII (585-bp deletion) and NsiI-ApaI (172-bp deletion), respectively. To
construct transgenes 5, 10, 11, and 12, a 2.3-kb fragment containing the minimal
promoter of the thymidine kinase (TK) gene from the Herpes simplex virus
upstream of the human growth hormone (GH) gene was excised from plasmid
pTKGH (Nichols Institute) and cloned downstream of 13- and 9-kb POMC
segments from previously constructed plasmids. To construct transgene 13, two
human DNA fragments containing nPE1 and nPE2 were PCR amplified using
primers HP1 (5-TTTGAATTCCTGACCTCAAGCGATCCACCC-3) and
HP2 (5-CTAGGCTCAGATCTAGAGTCAAGCTCTGTG-3) that yield a 1.6-
kb product and HP3 (5-GACTCTAGATCTGAGCCTAGAATCATAGAA-3)
and HP4 (5-CCCGATATCTCTGCAGGCATCTGGACCTC-3) that yield a
1.2-kb product. Both fragments were ligated together via a natural XbaI site
(underlined in the primer sequences) and subcloned into the pTrap vector (42)
upstream of the minimal promoter of the chicken -globin gene and the lacZ
reporter gene. Sequence quality was assessed by automated PCR sequencing.
Prior to microinjection, all transgenes were digested with appropriate restriction
enzymes to discard vector sequences, size fractionated on agarose gels, and
purified using Elutip columns (Schleicher and Schuell). Different reporter cas-
settes were used in this study according to methodological or practical reasons.
Enhanced green fluorescent protein (EGFP) has been previously used by our
group for the identification of live POMC neurons (13, 24), whereas the lacZ and
human growth hormone cassettes were chosen because they contain expression-
less minimal promoters and convenient upstream polylinkers and encode trans-
genic products that facilitate colocalization experiments with antibodies against
Pomc peptides.
Production of transgenic mice. Transgenic mice were generated by pronuclear
microinjection of B6CBF2 or B6D2F2 zygotes as described previously (66).
Microinjected zygotes were transferred to the oviduct of NIH or B6CB pseudo-
pregnant females. Transgenic pups were identified by tail genomic DNA PCR as
described previously (66). For transgenes 1 to 4 and 6 to 9, primers M329
(5-GAAGTACGTCATGGGTCACT-3) and M330 (5-AGCTCCCTCTTGAA
CTCTAG-3), which identify a heterologous insertion present in exon 3 of the
transgenes (66), were used. For transgenes 5 and 10 to 12, primers TK (5-CA
GCGTCTTGTCATTGGCG-3) and GH (5-AGTGGTTCGGGGAGTTGGG-
3), which amplify a 170-bp product from the TKGH sequence, were used, and
for transgene 13, primers HP3 and PPH9 (5-TCAAGGGCAAAGAGGAATC
A-3), which amplify an 800-bp, human-specific product, were used. The num-
bers of independent transgenic lines (in parentheses) analyzed for each trans-
gene were as follows: transgene 1 (1), transgene 2 (2), transgene 3 (2), transgene
4 (1), transgene 5 (3), transgene 6 (1), transgene 7 (2), transgene 8 (2), transgene
9 (5), transgene 10 (2), transgene 11 (1), transgene 12 (5), transgene 13 (3). All
animal procedures were conducted in accordance with the Guide for the Care
and Use of Laboratory Animals by the U.S. Public Health Service.
Immunohistochemistry. Mice were perfused with 4% paraformaldehyde
(PFA) in KPBS (0.9% NaCl, 16 mM K2HPO4, 3.6 mM KH2PO4), and brains
were excised, postfixed in 4% PFA–KPBS overnight at 4°C, and sectioned (50
m) with Vibratome 1000 (Ted Pella, Redding, Calif.). Brain slices were treated
with 1% H2O2 in KPBS for 20 min, washed twice with KPBS, and incubated
overnight at 4°C with the primary antibodies diluted in KPBS–0.3% Triton X-100
and 2% normal goat serum. The primary antibodies were rabbit polyclonal
anti-ACTH–IC-1 (1:1,000; National Hormone and Pituitary Program, National
Institutes of Health [NIH]), anti-EGFP ab290 (1:10,000; AbCam), and anti-
hGH–IC-3 (1:1,000; National Hormone and Pituitary Program, NIH) antibodies.
The next day, slices were washed in KPBS and incubated with biotinylated
anti-rabbit immunoglobulin G antibody (Vector) diluted 1:200 in KPBS–0.3%
Triton X-100 for 2 h at room temperature (RT). After washing in KPBS, slices
were incubated with avidin/biotin-horseradish peroxidase complex (Vectastain
Elite ABC kit; Vector) for 1 h at RT, washed in KPBS, and developed with 25
mg of diaminobenzidine (DAB; Sigma)/ml and 0.05% H2O2 in TBS (150 mM
NaCl, 50 mM Tris-HCl, pH 7.5). Alternatively, reactions were developed with a
blue chromogen (SG kit; Vector). Stained slices were then mounted onto gelatin-
coated slides.
Immunofluorescence. To check for colocalization of EGFP and POMC, brain
slices containing EGFP-expressing cells were subjected to an anti-ACTH immu-
nohistochemistry as described above up to the second antibody incubation and
then slices were incubated in streptavidin conjugated with Cy3 (1:800; Jackson
Immunoresearch) in KPBS for 1 h at RT. Subsequently slices were washed in
KPBS and mounted onto slides with FluorSave reagent (Calbiochem) and pho-
tographed with a microscope (Leica, Wetzlar, Germany) under UV light by using
different filters to check for colocalization of green (EGFP) and red (ACTH-
Cy3) fluorescence. The protocol for pituitaries was similar except that, prior to
immunohistochemistry, perfused pituitaries were dehydrated in an ascending
series of sucrose concentrations (10, 20, and 30% in PBS), frozen in embedding
medium (Tissue-Tek), and sectioned with a cryostat (Microm HM 505N; Micron,
Heidelberg, Germany) and then postfixed in 4% PFA.
Double in situ hybridization and immunohistochemistry. To colocalize en-
dogenous Pomc mRNA and the human GH (hGH) transgene product, nonra-
dioactive POMC in situ hybridization was performed and followed by anti-hGH
immunohistochemistry in 12-well plastic plates. A 600-bp mouse POMC exon 3
riboprobe was synthesized using a DIG-labeling kit (Roche) according to the
instructions of the manufacturer. PFA-fixed, Vibratome-sectioned brain slices
were treated with 0.1 M triethanolamine (TEA), pH 8.0, for 3 min, followed by
an incubation in 0.0025% acetic anhydride in 0.1 M TEA for 10 min to block
positive charges, and washed twice in 2 SSC (0.3 M NaCl, 0.03 M sodium
citrate, pH 7.2). Brain slices were incubated in hybridization solution (50%
formamide, 200 mM NaCl, 1 Denhardt’s solution, 1 mM EDTA, 10 mM
Tris-HCl [pH 8.0], 10% dextran sulfate) for 2 h at 57°C. The riboprobe was
heated at 65°C for 5 min (in 100 l of water with 5 g of tRNA) and added to
the hybridization solution of each well. Hybridization followed overnight at 57°C.
The next day, slices were washed for 10 s in 2 SSC and subjected to RNase A
digestion (20 g of RNase A/ml, 50 mM NaCl, 10 mM Tris-HCl [pH 8.0], 1 mM
EDTA [pH 8.0]) at 37°C for 30 min, de-salted in 1 and 0.25 SSC for 30 min
at 60°C. Slices were washed in buffer 1 (0.1 M Tris-HCl [pH 7.5], 0.15 M NaCl)
and incubated with anti-DIG mouse monoclonal antibody (1:5,000; Jackson
ImmunoResearch) in buffer 1 containing 0.2% normal goat serum for 2 h at
37°C. Slides were then washed once in buffer 1 and once in KPBS and incubated
with goat biotinylated anti-mouse immunoglobulin G antibody (1:200, Vector)
for 2 h at RT and then developed with DAB as described above. After that, slides
were washed in KPBS and then incubated with anti-hGH (1:1,000) and finally
developed with benzidine hydrochloride (Sigma) as described in reference 18.
Radioactive in situ hybridization of pituitaries. Pituitaries were fresh frozen in
embedding medium (Tissue-Tek), and 12-m-thick sections were collected on
gelatinized glass slides with a cryostat microtome (Microm HM 505N; Micron).
A 176-nucleotide riboprobe labeled with [-35S]UTP was synthesized from a
plasmid containing part of exon 5 of the hGH gene by using the MAXIscript kit
(Ambion). The in situ hybridization was performed as described previously (66).
X-Gal staining. The 50-m-thick Vibratome brain slices of transgenic mice
carrying construct 11 were stained with 1 mg of 5-bromo-4-chloro-3-indolyl--
D-glucuronic acid (X-Gal)/ml in staining solution (PBS [pH 7.3] containing 2.12
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mg of potassium ferrocyanide/ml, 1.64 mg of potassium ferricyanide/ml, 2 mM
MgCl2, 0.01% sodium deoxycolate, and 0.02% NP-40) for 4 h at 37°C. Stained
slices were then subjected to anti-ACTH immunohistochemistry as described
above.
Isolation and partial mapping of bovine nPE sequences. A genomic clone
containing bovine nPE sequences was isolated from a bovine genomic phage
library (number BL1015, average insert size of 40 kb; Clontech) by a PCR-based
strategy (27) using degenerate primers for a conserved segment of nPE1: PPH7
(5-GACTGAGCTGAGTGCCTGT-3) and PPH3 (5-ANGAATGCNGAGTT
CTCCA-3). From this clone, partial sequences of nPE1 and nPE2 were ampli-
fied by PCR using primers PPH7 and PPH3 for nPE1 and PPH8 (5-GGATA
AAAGCNGTCTCAAGG-3) and PPH9 for nPE2, subcloned into pGEM-T
(Promega), and sequenced. The same clone also contained POMC exon 1 as
confirmed by performing PCR using primers specific for the exon 1 of the bovine
POMC gene (5- GGAAGTCCACTCAACGTC-3 and 5-CTGCGCCCTTAC
CTGTCA-3), which were designed based on a published sequence (GenBank
accession number J00016).
Sequences and programs. POMC loci sequences from human, mouse, rat,
chimpanzee, chick, and zebrafish were retrieved from the Ensembl website (http:
//www.ensembl.org). Partial dog sequences were retrieved from the National
Center for Biotechnology Information (NCBI) Trace database (http://www.ncbi
.nih.gov/Traces/trace.cgi). Takifugu rubripes and Xenopus tropicalis sequences
were retrieved from the Joint Genome Institute website (http://www.jgi.doe.gov).
Human and mouse sequences were compared using the DOTTER program (55)
downloaded from http://www.cgb.ki.se/cgb/groups/sonnhammer/Dotter.html, and
multiple sequences were compared using the PipMaker program (available at
http://bio.cse.psu.edu/pipmaker). Multiple alignments were done using the pro-
gram Clustal W (58) at http://www.ebi.ac.uk/clustalw. Identification of conserved
and aligned transcription factor binding sites was performed using the program
rVista2.0 (37) at http://www.dcode.org.
RESULTS
The region located between 13 and 9 kb of the mouse
POMC gene directs expression to hypothalamic neurons. Our
previous results showed that the region between 13 and 2
kb upstream of the mouse POMC transcriptional start site
contains enhancers capable of directing proper cell-specific
transgene expression to POMC neurons of the arcuate nucleus
of the hypothalamus (66). To facilitate the analysis of trans-
gene expression, we inserted the coding region of EGFP into
mouse Pomc exon 2 immediately before the translational start
codon of the POMC prohormone (Fig. 1, transgene 1). This
22-kb transgene containing the entire transcriptional unit of
mouse Pomc, together with 13 kb of 5 flanking regions and 2
kb of 3 flanking regions, drives accurate EGFP expression to
nearly 100% of that of POMC-expressing neurons in the ar-
cuate nucleus and has allowed for electrophysiological studies
of living POMC neurons (3, 13, 14, 24). To further narrow the
flanking regions necessary for Pomc expression in the brain, we
constructed two large deletions of transgene 1 by removing the
region between 6.5 and 0.8 kb or between 9 and 0.8 kb
(Fig. 1, transgenes 2 and 3). The expression pattern of EGFP
was compared to that of endogenous Pomc in the serial brain
sections of transgenic mice carrying constructs 2 and 3 by using
EGFP and ACTH polyclonal antibodies. Colocalization of
EGFP in POMC neurons was assessed by red-fluorescent
immunohistochemistry coupled to the ACTH antibody on
Vibratome-sectioned brain slices of several independent trans-
genic mouse pedigrees. The analysis of deletion of transgenes
2 and 3 demonstrated that EGFP was coexpressed with Pomc
in neurons of the arcuate nucleus (Fig. 2A and B), as well as in
pituitary corticotrophs and melanotrophs (data not shown),
suggesting that the region between 9 and 0.8 kb is dispens-
able for neuron-specific expression of Pomc in the hypothala-
mus. In addition, complete deletion of the fragment spanning
from 13 to 9 (Fig. 1, transgene 4) prevented EGFP expres-
sion in the arcuate nucleus, although EGFP was properly ex-
pressed in pituitary corticotrophs and melanotrophs (data not
shown). Transgenes 1 and 4 showed a consistent ectopic ex-
pression of EGFP in the subgranular layer of the dentate gyrus
of the hippocampus probably due to the presence of a cryptic
enhancer located in the 2- to 0.8-kb region of the Pomc
promoter, as recently reported (41). These results suggest that
the 4-kb region located between 13 and 9 kb upstream of
the murine Pomc gene contains one or more neuronal enhanc-
ers necessary to direct Pomc expression to arcuate neurons.
We next sought to determine whether this 4-kb DNA region
was sufficient to direct transgene expression to POMC neurons
in the absence of the proximal Pomc promoter, which is known
to be essential for expression in pituitary melanotrophs and
corticotrophs. To this end, we constructed a transgene in which
the region from kb 13 to 9 from the mouse Pomc gene was
ligated upstream of a minimal heterologous promoter obtained
from the Herpes simplex virus TK gene, followed by the hGH
gene, which served as a reporter (Fig. 1, transgene 5). Trans-
genic mouse brains were analyzed for colocalization by in situ
hybridization against endogenous Pomc mRNA by using a
DIG-labeled riboprobe (developed with the brown chromogen
diaminobenzidine) followed by immunohistochemistry against
hGH (developed with the blue chromogen benzidine dihydro-
chloride). Interestingly, the fragment from positions 13 to
9 was able to target reporter gene expression to arcuate
POMC neurons (Fig. 2C and D) in the total absence of se-
quences from the proximal promoter, exons, introns, or 3
flanking regions of mouse Pomc, demonstrating that this distal
4-kb region contains neuronal-specific enhancer(s) sufficient to
drive transcription in POMC arcuate neurons. This result was
confirmed in three independent transgenic pedigrees that
showed an average of 75% of POMC-positive arcuate neurons
coexpressing the reporter hGH. Reporter gene expression was
not detected in pituitary melanotrophs (Fig. 2E and F). The
hGH riboprobe intensively labeled mouse somatotrophs in the
FIG. 1. First set of transgenes used in this study. Transgenes 1
through 4 carry the whole transcriptional unit of mouse Pomc with the
coding region of EGFP (E) inserted into exon 2 before the starting
translational codon. Pomc exons are indicated by black boxes. Trans-
gene 5 carries the distal enhancer region (kb 13 to 9) of mouse
Pomc upstream of the viral TK minimal promoter followed by the
hGH gene as reporter. Positive reporter expression in pituitary mela-
notrophs and corticotrophs (pit) and hypothalamic arcuate neurons
(arc) are indicated ().
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pituitary anterior lobe due to cross-hybridization with mouse
GH mRNA, precluding transgene expression analysis in corti-
cotrophs. Variable patterns of ectopic transgene expression
were also detected in the brains of these mouse lines in areas
that included the supraoptic nuclei of the hypothalamus, amyg-
dala, habenula, and cerebral cortex. Together, these results
demonstrate that distal neuronal enhancers located within the
13- to 9-kb region of the mouse Pomc 5 flanking region
are sufficient to drive reporter expression to POMC neurons of
the arcuate nucleus.
The Pomc neuron-specific region contains two highly con-
served elements in mouse and human. Among vertebrate ge-
nomes, regulatory elements are often more conserved than
average intergenic regions (16, 57). Therefore, in order to
identify candidate enhancers within the 13- to 9-kb mouse
Pomc fragment, we sequenced this 4-kb region and compared
it to the publicly available human POMC locus sequence. Fig-
ure 3A shows a global visualization of local sequence align-
ments (DOTTER program) (55) between the regions from kb
13 to 9 and kb 11 to 7 from the mouse and human
POMC genes, respectively. Two regions of approximately 600
and 150 bp with high identities between the two species were
readily identifiable. We named these two putative neuronal
POMC enhancers nPE1 and nPE2. In addition to the conser-
vation of nucleotide sequence, the distances from each ele-
ment to the transcriptional start were also similar, indicating
that the overall genomic organization at the POMC locus is
conserved between these two species (Fig. 3B).
Conservation of neuronal enhancer function in the human
POMC gene. To determine whether the homologous human
POMC region containing nPE1 and nPE2 sequences also has
the functional capability to target transgenic expression to ar-
cuate POMC neurons, we constructed a transgene in which the
region between 11 and 8 kb of the human POMC gene
(containing both nPE regions [Fig. 3]) was ligated upstream of
the minimal promoter of the chicken -globin gene followed by
the lacZ reporter gene (transgene 13 [Fig. 4A]). -Galactosi-
dase (-Gal) activity was visualized in situ followed by immu-
nohistochemistry against ACTH in coronal brain sections of
transgenic mice from three independent pedigrees. Interest-
ingly, X-Gal blue staining was evident in POMC-positive ar-
cuate neurons (Fig. 4B and C), although the percentage of
FIG. 2. Reporter gene expression in the arcuate nuclei and pitu-
itary glands of transgenic mice. (A and B) Coronal brain sections of a
transgene 3 mouse immunostained for ACTH (panel A) and EGFP
(panel B). The inset in panel B shows an example of colocalization of
EGFP fluorescence (green) and ACTH immunofluorescence (red) in
the arcuate of a transgene 3 mouse. (C) Coronal section of a transgene
4 mouse brain immunostained for hGH. (D) Colocalization of Pomc
mRNA and hGH in the arcuate of a transgene 5 mouse. Brain slices
were subjected to nonradioactive Pomc in situ hybridization (brown)
followed by hGH immunostaining (dark blue granules). (E and F)
Autoradiography of wild-type (panel E) and transgene 5 (panel F)
pituitary coronal sections hybridized with a 35S-radiolabeled hGH an-
tisense riboprobe. The probe detected endogenous GH mRNA in the
anterior lobe (AL) of both pituitaries but not in the intermediate (IL)
or neural (NL) lobes. Arc, arcuate nucleus; ME, median eminence; 3V,
third ventricle.
FIG. 3. Identification of nPE enhancers. (A) Global visualization of local sequence alignments between regions from kb 13 to 9 of the
mouse (vertical) and kb 11 to 7 of the human (horizontal) POMC genes by using the DOTTER program. Sequence conservation is shown as
dark dots in the graph, and colinear conserved stretches appear as diagonals. Two regions of high sequence identity are highlighted: nPE1 (600
bp) and nPE2 (150 bp). (B) Scheme of mouse and human POMC genes showing the relative positions of nPE regions. The three POMC exons are
numbered.
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colocalization was highly variable among the three pedigrees
analyzed (10, 68, and 95%). No reporter expression was de-
tected in pituitary melanotrophs or corticotrophs (Fig. 4D).
Different levels of ectopic -Gal expression were observed in
the brain of each transgenic pedigree in regions that included
the amygdala, the habenula, the hippocampus, the cerebral
cortex; the lateral, ventromedial, and arcuate nuclei of the
hypothalamus; and some cells of the neural lobe of the
pituitary that do not express Pomc (Fig. 4D). These results,
together with those obtained from transgene 5 (see above),
indicate that neuronal POMC and pituitary POMC gene ex-
pression are controlled by topographically distinct and func-
tionally independent regulatory regions. In addition, the ability
of the human genomic fragment containing nPE1 and nPE2 to
target reporter expression to mouse POMC arcuate neurons
suggests that these conserved sequences play a role in the
expression of POMC in the human hypothalamus.
nPE1 and nPE2 are necessary to direct transgene expres-
sion to POMC arcuate neurons. Within the region spanning kb
13 to 9 of the mouse Pomc promoter, nPE1 and nPE2 are
the only nonrepetitive sequences that have been highly con-
served during mammalian evolution. This conservation sug-
gests that these sites may carry the necessary information
to assure neuronal-specific expression of the POMC gene. To
challenge this hypothesis, we constructed transgenic mice car-
rying deleted versions of the original POMC-EGFP transgene
from kb 13 to 8 in which nPE1, nPE2, or both enhancers
were deleted (transgenes 7, 8, and 9) (Fig. 5). EGFP expres-
sion and colocalization with POMC were determined in brain
and pituitary slices of transgenic mice. Transgenic mice lacking
either nPE1 (construct 7) or nPE2 (construct 8) reproducibly
targeted EGFP expression to over 90% of POMC-expressing
neurons in the arcuate nucleus (Fig. 6A and B), demonstrating
that the absence of either one of these elements was not suf-
ficient to disrupt neuronal-specific expression. A truncation
from kb 13 to 10.5 that removed nPE1, together with
neighboring sequences (transgene 6) (Fig. 5), also directed
eutopic expression of EGFP in POMC arcuate neurons (data
not shown), confirming that nPE1 is not absolutely necessary
to guarantee neuronal Pomc gene expression. Nevertheless,
the simultaneous deletion of nPE1 and nPE2 completely elim-
inated EGFP expression in POMC neurons of the arcuate in
five independent transgenic lines (Fig. 6C). All transgenic lines
carrying constructs 6, 7, 8, or 9 displayed EGFP expression in
pituitary melanotrophs and corticotrophs (Fig. 6D), confirming
that Pomc expression in the brain and pituitary gland is con-
trolled by independent enhancers. Together, these results in-
dicate that nPE1 and nPE2 function as neuronal transcrip-
tional enhancers that are necessary for Pomc expression in
arcuate neurons. In the absence of either one of these enhanc-
ers, the remaining element is still able to assure transgene
expression in POMC neurons of the arcuate nucleus, indicat-
ing a functional redundancy between nPE1 and nPE2.
To confirm the importance of these enhancers in directing
reporter expression to POMC arcuate neurons, we introduced
deletions of nPE1, nPE2, or both elements simultaneously into
the original transgene 5 in which a minimal viral TK promoter
was fused to the reporter gene hGH (transgenes 10, 11, and 12
[Fig. 5]). As observed with the previous set of larger trans-
genes, deletion of either nPE1 or nPE2 alone did not prevent
expression of reporter hGH in the arcuate POMC neurons
(results not shown). However, the simultaneous deletion of
both nPE1 and nPE2 completely abolished hGH expression in
FIG. 4. Conservation of human POMC enhancer function. (A)
Scheme of transgene 13. The region between kb 11 and 8 of the
human POMC gene was ligated upstream of the minimal promoter of
chick -globin and the lacZ transgene. nPE regions are indicated. (B)
X-Gal staining of the hypothalamus of a transgene 13 mouse showing
expression in the arcuate nucleus (Arc). (C) Colocalization of X-Gal
staining (blue) and ACTH immunoreactivity (brown) in arcuate neu-
rons. Arrows point to stained -Gal inclusion bodies in POMC neu-
rons; the arrowhead shows an example of a -Gal inclusion body that
does not colocalize with POMC. Abbreviations are as defined in the
legend to Fig. 2.
FIG. 5. Second set of transgenes used in this study. nPE enhancers
(gray boxes) were deleted from parental transgenes 1 and 5. Details
are as described for Fig. 1.
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the POMC arcuate neurons of five independent lines of trans-
genic mice as assessed by anti-hGH immunohistochemistry
(Fig. 6E and F). Transgenic mice carrying constructs 10, 11,
and 12 did not show reporter gene expression in pituitary
melanotrophs as predicted, but there was variable ectopic ex-
pression in the habenula, cerebral cortex, and hippocampus in
all lines, showing that the transgenes were not inserted into
transcriptionally silent regions (Fig. 6F, inset). These re-
sults further demonstrate that nPE1 and nPE2 are respon-
sible for the neuronal enhancer activity that we identified in
the fragment from kb 13 to 9 of the mouse Pomc 5 flank-
ing region.
nPE1 and nPE2 are conserved in mammals but not in other
vertebrates. Since the POMC gene is expressed in the ventro-
medial hypothalamic neurons of all vertebrate species studied
to date, we investigated whether the neuronal regulatory ele-
ments nPE1 and nPE2 are conserved in different vertebrate
orders. We searched the sequenced POMC loci from the com-
pleted genome projects of rat, chimpanzee, and chicken and
the teleost fishes pufferfish (T. rubripes) and zebrafish (Danio
rerio), as well as the ongoing genome projects of the dog and
the frog X. tropicalis (see Materials and Methods). Figure 7A
shows a multiple percentage-identity plot (PIP) (53) compar-
ing the human POMC locus to the complete mouse, rat, chim-
panzee, chicken, frog, pufferfish and zebra fish POMC loci, as
well as to a partial dog sequence. All mammalian sequences
showed extensive identity to the human POMC locus, including
several conserved noncoding blocks. Among these, nPE1 and
nPE2 displayed a particularly greater degree of conservation,
evidenced by long stretches and a high percentage of sequence
identity relative to those of other less conserved intergenic or
intronic regions. The chimpanzee POMC locus was almost
100% identical to the human locus in coding and noncoding
regions, as expected given the close evolutionary distance be-
tween these two primate species. In contrast, nonmammalian
POMC genes did not show significant blocks of sequence iden-
tity to the human POMC locus, except for exons 2 and 3
(chicken and Xenopus) and exon 3 (fishes). These data show
that both nPE1 and nPE2 are strongly conserved among mam-
mals but cannot be recognized in birds, amphibians, or teleost
fishes. Figure 7B shows a multiple alignment of nPE1 and
nPE2 of four different mammals, including partial nPE se-
quences that we amplified by PCR from a bovine genomic
phage clone containing the POMC gene. The alignment shows
several blocks of high sequence identity, which might indicate
possible binding sites for transcription factors. nPE1 had an
overall mouse and human similarity of 76%, with a 40-bp core
of 100% identity, whereas mouse and human nPE2 had 90%
similarity (138 bp out of 153 bp are identical). Interestingly, the
similarities between mouse and human exons 1, 2, and 3 of 64,
87, and 82%, respectively, were not higher than the interspe-
cies identity for nPE1 and nPE2.
A further comparison of human, mouse, dog, and cow nPE1
and nPE2 sequences by using the recently developed rVista
version 2.0 bioinformatics tool (37) allowed the detection of a
limited number of conserved and aligned transcription factor
binding sites that could determine the transcriptional regula-
tion of Pomc in arcuate neurons (Fig. 7B). Within nPE1, we
identified one site that carried two adjacent consensus se-
quences for the POU domain transcription factors Brn 4.0 and
OCT-1. Immediately downstream of this site was a consensus
sequence for Elf-2, a member of the Ets transcription factor
family. Interestingly, a sequence present at the 3 end of nPE1
highly matched a consensus binding site for signal transducer
and activator of transcription 3 (STAT3), a downstream effec-
tor of leptin known to upregulate Pomc transcription in hypo-
thalamic neurons. In addition, two conserved cAMP-respon-
sive element binding (CREB-like) sites were present within
nPE1.
Within nPE2, we identified a sequence that showed high
similarity to the consensus binding site for the homeobox gene
Nkx6.1 and the POU domain gene Brn2.0. Contiguous to this
site, there is a sequence that carries overlapping matches for
chicken ovoalbumin upstream promoter (COUP) and estro-
gen-related receptor alpha (ERR), two transcription factors
that belong to the orphan nuclear receptor family. Another
canonical ERR site was located further downstream.
FIG. 6. nPE enhancers are necessary for POMC expression in the
hypothalamus. (A through C) EGFP immunostainings performed on
coronal hypothalamic sections of transgene 7 (panel A), 8 (panel B),
and 9 (panel C) mice. Insets in panels A and B show colocalization of
EGFP (green) and ACTH immunofluorescence (red) in arcuate neu-
rons. Inset in panel C shows ectopic expression of transgene 9 in the
hippocampal dentate gyrus. Abbreviations as in Fig. 2. (D) Image of a
transgene 9 pituitary under UV light showing green fluorescence in
melanotrophs in the intermediate lobe (IL) and corticotrophs in the
anterior lobe (AL). NL, neural lobe. Panels on the right show colo-
calization of EGFP (green) and ACTH immunofluorescence (red) in
corticotrophs of a transgene 9 pituitary. (E and F) Immunostainings of
serial sagittal cuts of transgene 12 mouse hypothalamus. The arcuate
nucleus expresses ACTH (panel E) but not the hGH reporter (panel
F). The inset in panel F shows ectopic hGH expression surrounding
the anterior commissure in the same brain section.
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FIG. 7. Conservation of POMC neuronal enhancers. (A) Comparison of the human POMC gene to several species by using the program
PipMaker. The human POMC gene including 12 kb of the 5 sequence was compared to equivalent regions of the mouse (Mus musculus), rat
(Rattus norvegicus), chimpanzee (Pan troglodytes), chicken (Gallus gallus), frog (X. tropicalis), zebra fish (D. rerio), and pufferfish (T. rubripes), as
well as to a 4-kb region obtained from the Dog (Canis familiaris) Genome Project. The exons of human POMC as well as nPE regions are indicated.
For each species, alignments to human sequence are displayed by plotting the length and percent identity (between 50 and 100%) of aligned
segments. In the plot, short noncoding segments that appear conserved between mammals and nonmammalian species are usually simple repeats,
e.g., (AT)n, (GT)n. (B) ClustalW alignments of nPE1 and nPE2 enhancer regions from several mammalian species. H, human; M, mouse; C, dog;
B, cow (Bos taurus). Sequences from cows are incomplete. Identical residues are highlighted black. Colored boxes denote conserved and aligned
putative transcription factor binding sites.
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DISCUSSION
Identification of two neuronal enhancers that control POMC
gene expression in the central nervous system. The aim of the
present study was to identify functional cis-acting elements that
control neuronal POMC expression in the hypothalamus. In
the absence of POMC-expressing neuronal cell lines, we per-
formed a deletion and truncation analysis in transgenic mice
that provided a highly faithful and efficient expression system
in which to test the ability of different genomic regions to
target reporter gene expression to POMC hypothalamic neu-
rons. Here, we characterize two novel distal enhancers, nPE1
and nPE2, that play an essential role in the activation of POMC
gene expression in a selected population of hypothalamic ar-
cuate neurons. Our transgenic mouse and phylogenetic analy-
ses show that (i) a distal genomic region containing nPE1 and
nPE2 is necessary and sufficient to direct authentic neuron-
specific expression of reporter genes to POMC arcuate neu-
rons; (ii) either nPE1 or nPE2 assures proper reporter expres-
sion in POMC arcuate neurons, whereas simultaneous deletion
of these two enhancers completely eliminates expression in
POMC neurons; (iii) nPE1 and nPE2 nucleotide sequences
and genomic organization are both highly conserved among
mammals but not between mammals and birds, amphibians, or
fishes; (iv) the enhancer activity of mouse and human genomic
fragments containing nPE1 and nPE2 is functionally con-
served; (v) POMC expression in the brain and pituitary gland is
controlled by different and independent sets of enhancers; and
(vi) a limited number of conserved and aligned putative tran-
scription factor binding sites are present in these enhancers,
including canonical DNA sequences for STAT3 and for the
POU-domain proteins Brn 4.0 and OCT-1 in nPE1 and the
homeodomain factors Nkx6.1 and Brn2.0 in nPE2.
In the arcuate nucleus of the mouse hypothalamus, approx-
imately 3,000 POMC-expressing neurons are intermingled with
neurons that express other neuropeptides or monoamines, in-
cluding NPY/AGRP, ghrelin, somatostatin, or dopamine (13,
14, 51). The specific set of neuropeptides expressed in each of
these neuronal subpopulations is presumably determined by
particular combinations of transcription factors acting during
ontogenesis and subsequently in the maintenance of estab-
lished phenotypes. nPE enhancers probably play an important
role in these processes, acting as recognition sites for the as-
sembly of transcriptional complexes that participate in the
remodeling of chromatin structure at the POMC locus and the
expression of POMC in arcuate neurons. Although the mouse
and human regions containing nPE1 and nPE2 proved to be
necessary and sufficient to drive reporter gene expression to
POMC arcuate neurons of transgenic mice, they were not able
to isolate transgenes from the transcriptional influences
present at the insertion sites. In consequence, most transgenic
pedigrees that showed reporter expression in arcuate POMC
neurons also displayed variable patterns of ectopic transgene
expression.
Interestingly, our transgenic mouse analysis demonstrated
that nPE1 and nPE2 do not need to be simultaneously present
to direct transgene expression to POMC arcuate neurons, sug-
gesting some level of functional redundancy between these two
enhancers. Nevertheless, it is possible that each nPE enhancer
plays a unique role in POMC transcriptional regulation. For
example, leptin receptors localized in POMC arcuate neurons
signal via phosphorylated STAT3 and deficits in this signal
transduction pathway within these neurons correlate with very
low levels of POMC mRNA (2, 17). A recent study performed
in vitro using a heterologous cell line showed that STAT3
might increase POMC transcription by interacting with a non-
canonical STAT3 binding site located immediately upstream of
the TATAA box (39). Although it is still not known whether
phosphorylation of STAT3 activates Pomc expression directly,
nPE1 contains a STAT3 canonical site that is conserved and
aligned across mammals and could participate in the leptin
regulation of Pomc expression. Further studies are needed to
address this possibility.
Modular architecture of the POMC gene. Our results
showed that genomic mouse and human fragments containing
nPE1 and nPE2 fused to heterologous minimal promoters
direct the expression of transgenes to POMC arcuate neurons
in the absence of detectable reporter expression in pituitary
melanotrophs or corticotrophs (transgenes 5 and 13). On the
other hand, simultaneous deletion of nPE1 and nPE2 in the
context of the entire POMC transcriptional unit and flanking
regions abolishes reporter gene expression in the arcuate nu-
cleus while maintaining authentic transgenic expression in
pituitary POMC cells (transgene 9). Together, these results
indicate that two independent sets of enhancers control the
cell-specific expression of POMC: a distal module acting in the
brain and a proximal module acting in the pituitary. Whether
these two modular regions cross talk under particular physio-
logical circumstances to regulate POMC expression in the pi-
tuitary or the brain remains to be investigated. Our previous
studies demonstrated that all necessary elements to provide
cell-specific and hormonally regulated expression of transgenes
in pituitary POMC cells are located in approximately 300 bp
upstream of the rat or mouse TATAA box (33, 34). Moreover,
several transcription factors involved in pituitary POMC ex-
pression have been identified, including the homeobox protein
Pitx1, the T-box factor Tpit/Tbx19, and basic helix-loop-helix
proteins of the NeuroD1 subfamily (31, 32, 44). In contrast, the
transcription factors controlling POMC expression in the brain
are completely unknown. In this regard, nPE1 and nPE2 could
provide a valuable platform for the discovery of such factors.
Predictive analysis of binding sites based solely on computer
algorithms that identify canonical sequences generally yields a
high number of false positives (63) because transcription fac-
tors bind to short sequence motifs (6 to 12 bp) that occur very
frequently in a genome and different functional DNA elements
for the same transcription factor admit a considerable level of
degeneracy. However, novel bioinformatics tools have been
recently developed that select for canonical binding sites that
are aligned within highly conserved sequences of two or more
species. Using one of these tools, rVista2.0 (37), we were able
to identify five potential transcription factor binding sites along
the 600 bp of nPE1 and three sites along the 150 bp of nPE2
that complied with such stringent criteria. The high selective
pressure that these sequences withstood during more than 65
million years of evolutionary distance existing between mice
and men suggests that these sites play a key role in the com-
mitment of the POMC hypothalamic lineage and the cell-
specific and hormone-regulated expression of Pomc in the brain.
In fact, nPE1 contains a conserved and aligned site carrying
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two consecutive canonical sequences for Brn 4.0 and OCT-1,
two POU domain transcription factors that participate in the
final differentiation of glucagon-expressing pancreatic  cells
(26), and GnRH-expressing hypothalamic neurons, respec-
tively (9). This site is adjacent to a consensus sequence for
NERF/Elf-2, a member of the Ets transcription factor family.
The close proximity of these two sites suggests the existence of
a unique combination of a POU domain protein present in
POMC neurons that would heterodimerize with an Ets tran-
scription factor to control POMC expression. Both POU do-
main and Ets factors have been shown to form heterodimers to
activate gene expression. In fact, physical interaction of the
pituitary-specific POU homeodomain protein Pit-1 with Ets-1
has been shown to be critical to establish the lactotroph pitu-
itary lineage and to induce prolactin gene expression (5). nPE1
also contains a perfect canonical site for STAT3 whose poten-
tial significance in the leptin regulation of POMC expression
and the central control of satiety mechanisms have been ad-
dressed above. In addition, two separate conserved CREB-like
sites are present in nPE1, suggesting that transcription factors
from the leucine zipper family could also participate in the
neuronal regulation of POMC expression.
Within nPE2, there is a conserved and aligned homeodo-
main binding site carrying a canonical sequence for Nkx6.1 and
Brn2.0, two homeodomain transcription factors that partici-
pate in the final differentiation of pancreatic  cells (28) or
hypothalamic neuropeptide neurons expressing oxytocin, vaso-
pressin, and CRH (21), respectively. Binding of a homeobox or
POU domain factor to this site may be critical to induce neu-
ron-specific expression of POMC. Adjacent to this site, there
are overlapping canonical sequences for COUP and ERR,
two transcription factors that belong to the orphan nuclear
receptor family. The close proximity of these two binding sites
suggests that an orphan nuclear receptor may physically inter-
act with a homeodomain factor to repress POMC expression.
Such a type of transcriptional repression has been observed
between the homeodomain protein Pit-1 and different mem-
bers of the orphan nuclear receptor factor family (20). An
additional ERR site is located further downstream at the 3
end of nPE2. ERR participates in the control of energy bal-
ance by regulating the mitochondrial -oxidation of fatty acids
(62) as well as the development of brown and white adipocytes
(38, 64). ERR-induced transcriptional regulation of hypotha-
lamic POMC could provide another level for the control of
energy homeostasis by regulating food intake in concert with
leptin and NPY activation of POMC neurons. Taken together,
it is tempting to speculate that some, if not all, of these highly
conserved and aligned binding sites are the cis-acting platforms
where unique clusters of transcription factors present in hypo-
thalamic POMC neurons are recruited to specifically transac-
tivate POMC. Additional functional and biochemical assays
will have to be performed in order to finally characterize the
cis- and trans-acting partners that control neuronal POMC
expression.
The independent modular architecture of the POMC gene
may also have important implications in the study of genetic
predisposition to familial obesity. Total POMC deficiency
causes a complicated syndrome that includes adrenal insuffi-
ciency, skin and hair pigmentation deficits, and early-onset
obesity probably due to the lack of ACTH and peripheral and
central melanocortins, respectively (8, 29, 65). Although ho-
mozygous null mutations of POMC are extremely rare in hu-
mans, genome-wide QTL scans have demonstrated a genetic
linkage between obesity-related traits and a region in human
chromosome 2 containing the POMC locus with a reported
logarithm of odds score of 7.5, the highest ever found in a
human genetic study of obesity-related traits (reviewed in ref-
erence 12). This linkage first determined in a population of
Mexican-Americans has been reproduced in other studies that
analyzed individuals of Caucasian French and African-Amer-
ican origins (23, 25, 47). Although the strongest candidate gene
for this chromosome 2 QTL is POMC, no loss-of-function
mutations were found within the POMC transcriptional unit
(25). Therefore, it is tempting to speculate about the possibility
that polymorphisms or mutations in nPE1 and nPE2 could
decrease the transcription of POMC and thereby the neural
content of POMC peptides, impairing central energy homeo-
static mechanisms and predisposing to excessive weight gain
without altering the levels or physiological actions of pituitary-
released POMC products. Thus, nPE regions are natural can-
didates to screen for sequence polymorphisms that influence
human obesity.
Phylogenetic footprinting to identify neuronal POMC en-
hancers. Until recently, it was difficult to predict the localiza-
tion of transcriptional regulatory elements based solely on
nucleotide sequence analysis. However, the recent availability
of genomic sequences from an increasing number of vertebrate
species has allowed the identification of regulatory regions by
comparing homologous intergenic regions from different spe-
cies, a technique termed phylogenetic footprinting (16, 36, 57).
This strategy is based on the idea that, as a result of selective
pressure, mutations accumulate faster in nonfunctional nucle-
otide residues whereas functional residues remain more con-
served. Therefore, multiple alignment comparisons between
orthologous gene loci allow the discovery of potential regula-
tory sequences embedded in large intergenic regions.
In the study reported here, we combined phylogenetic foot-
printing with expression analysis in transgenic mice to identify
two POMC neuronal enhancers. We found nPE1 and nPE2 in
representative species of the mammalian orders Rodentia, Pri-
mates, Carnivora, and Artiodactyla, and it is reasonable to
predict that nPEs will be found in all mammals. Conversely, we
failed to identify conserved nPE enhancers outside Mammalia
in spite of the fact that POMC is expressed in the ventromedial
hypothalamus of the chicken and teleost fishes like trout, gold-
fish, and zebrafish (7, 19, 35, 59). Even though there are several
examples of enhancers conserved among mammals, birds, and
fishes (1, 6, 22, 48, 61), the only conserved regions we observed
after comparing the human POMC locus with orthologous
genomic sequences from other nonmammalian vertebrates
were coding exons 2 and 3. Nevertheless, given that hypotha-
lamic expression of POMC is a conserved vertebrate feature
and that core recognition sites for transcription factors are
usually very short (6 to 10 bp), it is likely that a similar set of
transcription factors control POMC expression in all verte-
brates but that the accumulation of neutral mutations through-
out evolution prevented us from identifying neuronal POMC
enhancers by global alignment programs. The example of
POMC illustrates the fact that for each gene, a different set of
species might be necessary to obtain useful results by phyloge-
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netic footprinting. In this case, the human X mouse compari-
son provided an optimal degree of sequence conservation for
the identification of functional enhancers while the human X
chimpanzee pair was too similar and the sequences of birds,
amphibians, or fishes was too different.
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